Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.

de Souza, Roseane Porfírio; Ribeiro, Andre Luis Ribeiro; de Menezes, Sílvio Augusto Fernandes; Machado, Luiz Fernando Almeida

de Souza, Roseane Porfírio; Ribeiro, Andre Luis Ribeiro; de Menezes, Sílvio Augusto Fernandes; Machado, Luiz Fernando Almeida.

Afiliação

de Souza RP; Biology of Infectious and Parasitic Agents Post-Graduate Program, Federal University of Pará, Belém, Pará, Brazil.
Ribeiro ALR; Gaspar Vianna Clinic Hospital Foundation, Belém, Pará, Brazil.
de Menezes SAF; Postdoctoral fellowship, Cell Culture Laboratory, School of Dentistry, Federal University of Para - UFPA, Belém, Pará, Brazil.
Machado LFA; Clinical lecturer, Department of Periodontology, School of Dentistry, University Centre of Para - CESUPA, Belém, Pará, Brazil.

BMC Pediatr ; 19(1): 299, 2019 08 28.

Article em En | MEDLINE | ID: mdl-31462289

RESUMO

BACKGROUND: Palivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk of developing severe lower respiratory tract infection (LRTI) due to HRSV infection. Our goal was to evaluate the incidence of HRSV infection in children with CHD after being submitted to immunoprophylaxis with palivizumab in Pará state, North region of Brazil. METHODS: A prospective and observational cohort study was performed in children ≤2 years of age with CHD who received palivizumab immunoprophylaxis between January 1 and June 31, 2016. A questionnaire about basic non-medical care measures was applied to parents/legal representatives. Data on patients' demographic characteristics, household environment, and respiratory infections were evaluated. HRSV infection was determined by qPCR. RESULTS: There were 104 children enrolled in this investigation and the results showed a mean age of 10.6 months, an average weight of 7.3 kg and 3.5 doses of palivizumab per children during seasonality of HRSV. Respiratory infection was observed in 27.9% of cases, of which 9.6% were LRTI. No case of children who received palivizumab immunoprophylaxis and developed influenza-like symptoms tested positive for HRSV. CONCLUSION: Although the lack of a control group doesn't allow to affirm the effectiveness of HRSV passive immunization, the immunoprophylaxis with palivizumab appeared to be totally efficient in preventing respiratory infection by HRSV in children up to two years of age with CHD.

Assuntos

Antivirais/uso terapêutico; Cardiopatias Congênitas/epidemiologia; Palivizumab/uso terapêutico; Infecções por Vírus Respiratório Sincicial/epidemiologia; Infecções por Vírus Respiratório Sincicial/prevenção & controle; Brasil/epidemiologia; Feminino; Humanos; Imunização; Incidência; Lactente; Recém-Nascido; Masculino; Estudos Prospectivos

Palavras-chave

Immunization; Palivizumab; Respiratory syncytial virus; Respiratory tract infections

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por Vírus Respiratório Sincicial / Palivizumab / Cardiopatias Congênitas Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Infant / Male / Newborn País/Região como assunto: America do sul / Brasil Idioma: En Revista: BMC Pediatr Assunto da revista: PEDIATRIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google